IAFSC
The Interfaith Alliance for Safer Communities (IAFSC), an NGO established to empower faith leaders to work for the safety and security of communities, has held a successful online interfaith roundtable event with representation from 50 participants representing 7 faiths from 18 countries.
Speaking about the event, Dr. Vinu Aram (Director of Shanti Ashram and Co-Moderator of Religions for Peace) said, “I want to thank the Interfaith Alliance for Safer Communities for this meeting today. The work of the Interfaith Alliance is so important: in the disruption of the ways we worked together as communities during Covid-19, we have found that children have become more vulnerable... While every nation is trying to find its own solution, those of us who work with children have to be greater advocates for their cause.”
Chief Executive of the IAFSC, Dana Humaid, said “Faith has rarely been more important or powerful than in the current crisis. The IAFSC hosted this event in order to allow discussion and facilitate knowledge-sharing from different religions and communities on a global scale. Faith leaders have the power to assist their communities, to be advocates for those in need, to make a difference and offer comfort and also to try and reduce the suffering of people under their watch.”
The ongoing Covid-19 pandemic has been unprecedented in modern times, and has had a significant impact on the physical, mental and spiritual wellbeing of our communities. Millions have lost their jobs and are facing struggles such as hunger and homelessness. This pandemic has had unforeseen consequences as well, such as a surge in the cases of child sexual abuse as well as an increase in hate crimes based on race and religion.
Key Outcomes
The roundtable discussions aimed to address the most significant problems being faced by our communities today.
Supporting those most impacted by coronavirus in rebuilding their lives
- We are all impacted by this pandemic, we are not all affected the same way.
- The role of faith and faith leaders is to build, promote and invigorate a spirit of resilience.
- When faith leaders aren’t able to contact their community and provide them with help or assistance in a difficult time, it is a challenge for everyone in the community.
- Faith leaders have been taking on the bulk of the work in some communities.
- We need to be careful of our blind spots, we cannot create a situation in which we overlook other communities that now need our help, such as those that may not be considered traditionally vulnerable sectors of society.
Protecting the digital dignity of children and supporting the victims and their families
- Faith leaders can be champions in leading the prevention of sexual exploitation.
- It is important to base our responses on data and evidence and go from there.
- No one is an expert in the prevention of exploitation. Community is key.
- We need to increase budgets for social and health services.
- Family and family stability are also vital.
- Education, mobilization, support and universal healthcare are all necessary in improving our communities.
Among others, organisations represented included: Arigatou International, ECPAT International, New York Board of Rabbis, Conference of European Rabbis, Bahá'í International Community, Peres Center for Peace and Innovation, Shanti Ashram, World Economic Forum, UNICEF, Conference of European Churches, Markaz Knowledge City (India), and Online Anti-Semitism Task Force.
Visit https://iafsc.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200907005253/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
